{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:55:08Z","timestamp":1788155708541,"version":"build-2803163510"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Real\u2010world data (RWD) for paliperidone palmitate (PP) three\u2010monthly (PP3M) is lacking based on Japan label requirements. This study evaluated the clinical effectiveness of PP3M versus PP once\u2010monthly (PP1M) in patients with schizophrenia administered according to Japan label requirements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analyses were conducted using RWD from Merative\u2122 MarketScan\u00ae Multi\u2010State Medicaid (MDCD) claims database (June 2015\u2013December 2022). Adult patients with schizophrenia switching from PP1M to PP3M were included. Patients transitioning to PP3M were matched with patients who continued with PP1M using propensity score matching (PSM) at 1:1 ratio. Primary hypothesis aimed to investigate non\u2010inferiority of PP3M versus PP1M in terms of relapse\u2010free status at 24\u2009months from index PP injection. Outcome measures were proportions of relapse\u2010free patients at 24\u2009months, time to relapse, treatment persistence, and adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Total 4252 eligible adult schizophrenia patients on PP (PP3M:582; PP1M:3670) were identified. After PSM, each PP cohort comprised 562 matched individuals. Estimated proportion of relapse\u2010free patients was higher in PP3M (85.7%) versus PP1M (77.9%), per Japan PP label. PP3M demonstrated superiority to PP1M after testing for non\u2010inferiority in terms of achieving relapse\u2010free status at 24\u2009months, with an estimated difference of 7.8% (95% CI: 1.7%\u201313.9%). PP3M cohort had lower risk of relapse (HR: 0.605; CI: 0.427\u20130.856), longer treatment persistence, and higher treatment adherence versus PP1M cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings suggests that patients who switched to PP3M might be able to reduce risk of relapse compared to those who continued PP1M after aligning particularly with Japan's label requirements.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/npr2.12473","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T15:39:08Z","timestamp":1726069148000},"page":"716-727","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical effectiveness of paliperidone palmitate 3\u2010monthly and 1\u2010monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database"],"prefix":"10.1002","volume":"44","author":[{"given":"Chih\u2010Lin","family":"Chiang","sequence":"first","affiliation":[{"name":"Medical Affairs, Johnson &amp; Johnson Innovative Medicine  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Chinen","sequence":"additional","affiliation":[{"name":"Medical Affairs, Janssen Pharmaceutical K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Daskiran","sequence":"additional","affiliation":[{"name":"US Statistics &amp; Decision Sciences, Janssen Research &amp; Development, LLC  Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Wakamatsu","sequence":"additional","affiliation":[{"name":"Medical Affairs, Janssen Pharmaceutical K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Turkoz","sequence":"additional","affiliation":[{"name":"US Statistics &amp; Decision Sciences, Janssen Research &amp; Development, LLC  Titusville New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"WHO Schizophrenia World Health Organization. Available from:https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/schizophrenia. Accessed 23 May 2024."},{"key":"e_1_2_12_3_1","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel KR","year":"2014","journal-title":"P T"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02138-4"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04044-5"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12050674"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.05.016"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.12.010"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0278-3"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02252-9"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13304"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.02.020"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-clinpsy-032813-153657"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.11.020"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.1001514"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08440"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp140219"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-221"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.9.754"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.751025"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10081224"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903482772"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S400342"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab071"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0241"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw018"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S322880"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01556-4"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz068"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2021.19.3.434"},{"key":"e_1_2_12_31_1","unstructured":"Janssen PharmaceuticalKK.XEPLION TRI (paliperidone palmitate) Aqueous Suspension for IM Injection. [package insert]."},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S134287"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0416-1"},{"key":"e_1_2_12_34_1","volume-title":"INVEGA TRINZA (paliperidone palmitate) Prescribing Information","author":"Janssen Pharmaceuticals","year":"2021"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00917-1"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.22.1017"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.433"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.4.346"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1322"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbx176"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.2023496"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2022.01.044"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201200156"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S39303"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16m11308"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2019.07.138"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001704"}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12473","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/npr2.12473","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:36:58Z","timestamp":1773013018000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.12473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/npr2.12473"],"URL":"https:\/\/doi.org\/10.1002\/npr2.12473","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"2024-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}